Table 2 Adverse events after single round of Ad5/3-cox2L-D24 treatment

From: Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

 

Grade 1

Grade 2

Grade 3

Grade 4 or 5

General

 Chills

2

0

0

0

 Dizziness

1

2

0

0

 Dyspnea

0

1

0

0

 Fatigue

6

4

0

0

 Fever

6

3

0

0

 Flu-like syndrome

4

0

0

0

Metabolic or laboratory

 ALT increased

1

3

0

0

 AST increased

2

4

0

0

 ALP increased

0

1

0

0

 Hyperbilirubinemia

2

1

0

0

 Hyperkalemia

0

1

0

0

 Hypokalemia

0

0

1

0

 Hyponatremia

6

0

2

0

 INR increased

5

0

1

0

Cardiovascular

 Hypertension

3

0

0

0

Hematological

 Hemoglobin decreased

4

5

0

0

 Leukocytopenia

2

2

0

0

 Thrombocytopenia

2

0

1

0

Dermatological

 Urticaria

0

1

0

0

Gastrointestinal

 Anorexia

3

0

0

0

 Ileus

2

1

1

0

 Nausea

6

3

0

0

 Vomiting

1

1

0

0

Pain

 Back

1

1

0

0

 Bone

0

3

0

0

 Stomach

5

5

0

0

 Tumor

2

1

0

0

Other a

 Leukocytes increased

4

   

 Thrombocytes increased

3

   
  1. Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio for blood clotting.
  2. aNot graded as adverse events in CTCEA v3.0.
  3. All 18 patients were evaluated for adverse events (AE). Grade 1 AE is reported if shown by two or more patients. All grades 2–5 AEs are reported.